EP2515652A4 - Compositions et méthodes de traitement du vitiligo - Google Patents

Compositions et méthodes de traitement du vitiligo

Info

Publication number
EP2515652A4
EP2515652A4 EP10840093.8A EP10840093A EP2515652A4 EP 2515652 A4 EP2515652 A4 EP 2515652A4 EP 10840093 A EP10840093 A EP 10840093A EP 2515652 A4 EP2515652 A4 EP 2515652A4
Authority
EP
European Patent Office
Prior art keywords
vitiligo
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10840093.8A
Other languages
German (de)
English (en)
Other versions
EP2515652A1 (fr
Inventor
Sarah Bacus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
0901911 B. C. UNLIMITED LIABILITY COMPANY
Original Assignee
B C UNLIMITED LIABILITY Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B C UNLIMITED LIABILITY Co filed Critical B C UNLIMITED LIABILITY Co
Publication of EP2515652A1 publication Critical patent/EP2515652A1/fr
Publication of EP2515652A4 publication Critical patent/EP2515652A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
EP10840093.8A 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo Withdrawn EP2515652A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28868809P 2009-12-21 2009-12-21
US31567210P 2010-03-19 2010-03-19
PCT/US2010/061661 WO2011079154A1 (fr) 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo

Publications (2)

Publication Number Publication Date
EP2515652A1 EP2515652A1 (fr) 2012-10-31
EP2515652A4 true EP2515652A4 (fr) 2014-11-26

Family

ID=44196131

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10840093.8A Withdrawn EP2515652A4 (fr) 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo

Country Status (3)

Country Link
EP (1) EP2515652A4 (fr)
CA (1) CA2822746A1 (fr)
WO (1) WO2011079154A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2671583A4 (fr) * 2011-01-31 2014-09-03 Univ Osaka Médicament à usage externe pour traiter un trouble cutané et procédé pour produire celui-ci
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
CN104324367A (zh) * 2014-10-20 2015-02-04 广西壮族自治区花红药业股份有限公司 鱼鳞提取物在制备治疗和/或预防白癜风药物方面的新用途
JP2018528236A (ja) 2015-09-24 2018-09-27 ドレクセル ユニバーシティ 真皮障害を治療または予防するための新規組成物および方法
US10493020B2 (en) 2016-04-14 2019-12-03 The Procter & Gamble Company Method of improving the appearance of periorbital dyschromia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024036A1 (fr) * 1997-11-07 1999-05-20 Aberdeen University Composants ameliorant la penetration dans la peau
US20030022911A1 (en) * 2000-10-06 2003-01-30 Smith Terry J. Detection of antibody mediated inflammatory auto-immune disorders
WO2009118191A2 (fr) * 2008-03-27 2009-10-01 Clinuvel Pharmaceuticals Limited Thérapie pour le vitiligo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
EP1230917A1 (fr) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomes pour la thérapie des maladies, leurs fabrication et utilisation
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024036A1 (fr) * 1997-11-07 1999-05-20 Aberdeen University Composants ameliorant la penetration dans la peau
US20030022911A1 (en) * 2000-10-06 2003-01-30 Smith Terry J. Detection of antibody mediated inflammatory auto-immune disorders
WO2009118191A2 (fr) * 2008-03-27 2009-10-01 Clinuvel Pharmaceuticals Limited Thérapie pour le vitiligo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LISA B TRAVIS ET AL: "Successful Treatment of Vitiligo With 0.1% Tacrolimus Ointment The Cutting Edge: Challenges in Medical and Surgical Therapeutics REPORT OF CASES", ARCH DERMATOL, May 2003 (2003-05-01), pages 571 - 574, XP055146413, Retrieved from the Internet <URL:http://archderm.jamanetwork.com/data/Journals/DERM/11722/DCE20005.pdf> [retrieved on 20141014], DOI: 10.1001/archderm.139.5.571 *
PASSERON ET AL: "Physiopathology and genetics of vitiligo", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 25, 2005, pages 63 - 68, XP005176440, ISSN: 0896-8411, DOI: 10.1016/J.JAUT.2005.10.001 *
See also references of WO2011079154A1 *

Also Published As

Publication number Publication date
CA2822746A1 (fr) 2011-06-30
EP2515652A1 (fr) 2012-10-31
WO2011079154A1 (fr) 2011-06-30

Similar Documents

Publication Publication Date Title
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
EP2473054A4 (fr) Compositions et méthodes de traitement de la leucémie
EP2603202A4 (fr) Compositions et méthodes pour traiter une tauopathie
HK1226108A1 (zh) 用於癌症治療的診斷方法和組合物
ZA201105472B (en) Methods and compositions for diagnosis and treatment of cancer
ZA201006988B (en) Method and compositions for treatment of cancer
IL214455A0 (en) Methods and compositions for treatment of neovascularization
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
EP2429584A4 (fr) Procédés et compositions de traitement
GB0902040D0 (en) Composition for treatment of skin
IL214349A0 (en) Compositions and methods for the treatment of cancer
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
EP2437738A4 (fr) Procédés et compositions pour le traitement du cancer
EP2515652A4 (fr) Compositions et méthodes de traitement du vitiligo
EP2411031A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2473635A4 (fr) Compositions et procédés de traitement de la douleur névropathique
EP2411020A4 (fr) Compositions et procédés pour le traitement de l&#39;hémorragie
EP2462131A4 (fr) Compositions et procédés pour traiter des maladies associées au bêta-amyloïde
EP2440238A4 (fr) Méthodes de traitement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120716

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141023

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 8/49 20060101ALI20141017BHEP

Ipc: A61K 31/436 20060101ALI20141017BHEP

Ipc: A61K 31/555 20060101ALI20141017BHEP

Ipc: A61K 8/02 20060101AFI20141017BHEP

Ipc: A61Q 19/08 20060101ALI20141017BHEP

Ipc: A61Q 19/00 20060101ALI20141017BHEP

Ipc: A61K 45/06 20060101ALI20141017BHEP

Ipc: A61K 38/18 20060101ALI20141017BHEP

Ipc: A61Q 19/02 20060101ALI20141017BHEP

Ipc: A61K 9/06 20060101ALI20141017BHEP

Ipc: A61K 9/00 20060101ALI20141017BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 0901911 B. C. UNLIMITED LIABILITY COMPANY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: 0901911 B. C. UNLIMITED LIABILITY COMPANY

17Q First examination report despatched

Effective date: 20160523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20161024BHEP

Ipc: A61K 38/44 20060101AFI20161024BHEP

Ipc: A61K 31/555 20060101ALI20161024BHEP

Ipc: A61K 8/49 20060101ALI20161024BHEP

Ipc: A61K 31/407 20060101ALI20161024BHEP

Ipc: A61K 38/18 20060101ALI20161024BHEP

Ipc: A61Q 19/08 20060101ALI20161024BHEP

Ipc: A61K 9/00 20060101ALI20161024BHEP

Ipc: A61K 31/436 20060101ALI20161024BHEP

Ipc: A61K 9/06 20060101ALI20161024BHEP

INTG Intention to grant announced

Effective date: 20161117

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BACUS, SARAH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170328